ERBB2 and neoplasm: Ephrin type A receptor 2 (EphA2), IL-13Ra2, and HER2 represent promising tumor associated antigens that have been targeted both pre-clinically and clinically using CAR T-cell therapy in the setting of GBM (23, 133, 134).